TickerFacts.

Alumis Inc. (ALMS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$301.30M
As of 2025-12-31
$452.16M
As of 2026-06-30
2023-12-31: -$339.26M2024-12-31: $260.10M2025-12-31: $301.30M$301.30M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$301.30M+15.8%2026-03-19, Balance as of period end
2024-12-31$260.10Mn/m2026-03-19, Balance as of period end
2023-12-31-$339.26Mn/a2025-03-19, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Alumis Inc. (ALMS)2025-12-31$301.30M+15.8%
Entrada Therapeutics, Inc. (TRDA)2025-12-31$306.13M-28.6%
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$683.43M-9.8%
Celularity Inc (CELU)2025-12-31-$38.06Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31$26.43M+51.0%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$37.28Mn/m
Scynexis Inc (SCYX)2025-12-31$49.38M-10.4%
Evofem Biosciences, Inc. (EVFM)2025-12-31-$74.34Mn/m
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$22.81M-20.9%

Compare ALMS, TRDA, NAMS, CELU side by side · Screen every company in Pharmaceutical Preparations ↗